Pelthos Therapeutics $PTHS Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up Pelthos Therapeutics Inc. ($PTHS). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-10-01. 17 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-05-21. Non-reliance (8-K Item 4.02) filed 2026-08-13.
🔖 Exposure: revenue $16.8M (FY2025). Experience: one year on record; operating margin -193.1%, up from null. Soundness: equity 29.8% of assets, return on equity -111.4%. Credibility: 2 audited years, little weight, marked down from moderate: on 2026-08-13 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -193.1% against a -15.8% median.
Speed and cash · fiscal 2025
| Cash flow (op · inv · fin · free) | −$23M · −$5M · $45M · −$23M |
| Investment book (cash · short · long) | $18M · — · — · current ratio 2.05 |
| Revenue swing · equity of assets | — · 29.8% |
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $17M |
| Revenue, on the year | — |
| Revenue, a year over the record | — |
| Operating margin | −193.1% |
| Operating margin, prior year | — |
| Net margin | −257.9% |
| Research and development | $1M · 7.3% of revenue |
| Total debt | — |
| Equity of assets | 29.8% |
| Return on equity | −111.4% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-23.04 |
| Book value per share | $20.68 |
| Revenue per share | $8.93 |
| Shares outstanding | 1,880,498 |
| Audited years read | 2 |
Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).
Health HarborPelthos Therapeutics sails as: Weathered boat
Health watch · 12 monthsEarlier statements no longer to be relied onAuditor changeDirector or officer change ×5
No growth figure to set the speed.
🌊 Visit the Bay →- filed earlier statements no longer to be relied on, auditor change in the last 12 months
- operating cash flow was negative
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-10-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits
- DEF 14A · 2026-08-18
- 10-Q · 2026-08-13
- 8-K · 2026-08-13 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-13 · 4.02 Non-Reliance on Previously Issued Financial Statements
- 8-K · 2026-05-28 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company